Construction workers break ground on first-of-its-kind nuclear facility: 'The most significant development'
According to Romania Insider, construction of Europe's very first tritium removal facility began in early June 2025. This would put the facility in a great position for future nuclear fusion processes.
The work is happening at a nuclear power plant in Cernavodă and was called "the most significant development in Romania's nuclear sector since the commissioning of Cernavodă's Unit 2 reactor" by Sebastian Burduja, the Minister of Energy in Romania, according to Romania Insider.
In simple terms, nuclear energy works by harnessing the energy contained in an atom's nucleus — either by splitting the atom (in nuclear fission) or by combining atoms (in nuclear fusion).
"Nuclear fusion is the process by which two light atomic nuclei combine to form a single heavier one while releasing massive amounts of energy," the International Atomic Energy Agency has stated.
By removing tritium from the water used in existing nuclear fission reactors, the water can, in turn, be reused, and the tritium stored for fuel in future nuclear fusion reactors — as Romania Insider explained. This process conserves two vital resources at once.
"This project positions Romania among the few countries capable of producing and exporting tritium — seen as the fuel of the future for fusion energy programs …" Energy Minister Burduja said to the news outlet.
Nuclear energy is the largest source of "clean energy" in the U.S, according to the Department of Energy (defining it as clean energy because it produces almost no carbon pollution). It can supply energy on demand — unlike wind and solar, which rely on the weather or time of day — making the move away from dirty fuel sources more seamless.
Nuclear fission, which generates electricity today, does create radioactive waste and has a history of uncommon but significant disasters. By comparison, nuclear fusion, which is still in development for producing electricity, has advantages that include not creating long-lived radioactive waste while producing abundant clean energy.
Investing in renewable energy for your home is another way to tap into the benefits of pollution-free energy — such as cleaner air, a smaller carbon footprint, and cheaper utility bills. A straightforward way of doing this is the installation of rooftop solar panels.
Should we be pouring money into nuclear fusion technology?
Yes — it'll pay off
It's worth exploring
Not from our tax dollars
No — it's a waste
Click your choice to see results and speak your mind.
Not only can these panels bring your personal electric bill down to at or near $0 a month, but they also don't release the toxic, heat-trapping fumes that are produced by power plants that rely on coal, gas, or oil.
EnergySage provides a free service that makes it easy to compare quotes from vetted local installers and save up to $10,000 on your new solar installations.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Musk's Neuralink to test brain chips in clinical study in Great Britain
(Reuters) - Elon Musk's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, according to media reports, citing PitchBook.
Yahoo
4 hours ago
- Yahoo
This Stock Is Up by 800% This Year -- but Is It a Buy?
Key Points Abivax's shares skyrocketed following positive clinical trial results for its lead candidate, obefazimod. This investigational medicine could prove more effective than existing drugs for ulcerative colitis. There might be plenty of upside left if obefazimod produces more positive results in further trials. 10 stocks we like better than Abivax Société Anonyme › If you had invested money in Abivax (NASDAQ: ABVX) at the beginning of the year, you would be sitting pretty right now. The French biotech's shares recently skyrocketed and are up more than 800% year to date. As investors can probably guess, Abivax's gains are tied to impressive clinical progress for its leading pipeline candidate. However, some might worry that it's too late to buy the stock now. Is that the case? Let's look deeper into what's going on with Abivax and determine whether there's any upside left. A potential first-in-class drug Abivax's leading pipeline candidate is called obefazimod, a potential treatment for ulcerative colitis (UC). It could be a first-in-class drug, meaning a medicine that has a novel mechanism of action distinct from those of existing therapies targeting the same condition. First-in-class drugs sometimes prove more effective than standard existing treatments, so there is significant potential for a smaller biotech company working on a medicine like this one, if it can ace clinical trials. Abivax has just achieved exactly that, with strong results from a pair of phase 3 trials for obefazimod. The medicine led to a high rate of remission among participants with moderate to severely active UC, compared to a placebo. Importantly, the studies included patients who had never received any advanced therapy for UC, as well as some who had but had previously failed to achieve remission. According to Abivax, 47.3% of participants in these trials had an inadequate response to prior therapy. In other words, obefazimod succeeded in helping some patients achieve remission where other medicines had failed. And this isn't an obscure therapeutic area with just a couple of options, either: It's actually a highly competitive market. There are numerous advanced therapies for UC, including some produced by several of the world's largest pharmaceutical companies. That makes obefazimod's success all the more impressive. Why it may not be too late to buy the stock Abivax's market capitalization is now 3.7 billion euros (about $4.3 billion). Some analysts estimate that obefazimod could hit peak sales of about $4 billion. Of course, it won't get there anytime soon, even if it earns approval. Though the data looks strong so far, there is more to come. The recent results Abivax shared were from induction trials (to see whether a medicine can reduce the symptoms of a disease). The biotech has an ongoing maintenance study (to check whether it can keep the disease under control), the results of which it plans to share in the second quarter of 2026. If this data isn't up to Wall Street's liking, Abivax's shares might plunge. That's to say nothing of potential regulatory setbacks, which aren't that rare with smaller biotech companies and could also sink the company's stock price. So there are some risks involved, but the stock might be worth it for those who can stomach the volatility. Abivax has developed a medicine with a novel mechanism of action that performs well in clinical trials, and that ability speaks volumes about the company's innovative capabilities. Meanwhile, although funding was an issue at the start of the year, it should no longer be a problem. Abivax ended the first quarter with 103.6 million euros in cash ($120.1 million), which management thought would only last until the end of this year. Thanks to obefazimod's phase 3 results and the company's stock price soaring, Abivax announced a secondary offering, during which it expects to generate gross proceeds of 637.5 million euros ($747.5 million). That should be plenty of money for the company to keep the lights on, even beyond next year. There's still significant upside left if the ongoing phase 3 clinical trials for obefazimod in UC also yield strong results. Additionally, Abivax is testing its lead candidate as a monotherapy for Crohn's disease, as well as a potential combination treatment for UC. Consistent positive clinical and regulatory developments could lead to even more gains for patient investors. That's why it might still be time for those with above-average risk tolerance to initiate a small position in the stock. Should you buy stock in Abivax Société Anonyme right now? Before you buy stock in Abivax Société Anonyme, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Abivax Société Anonyme wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This Stock Is Up by 800% This Year -- but Is It a Buy? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
6 hours ago
- Medscape
Risankizumab Maintains Long-Term Effectiveness in Psoriasis
TOPLINE: Risankizumab was well tolerated and demonstrated sustained effectiveness and drug survival in patients with moderate-to-severe psoriasis over a period of 4 years. Obesity, difficult-to-treat sites, and prior biologic use delayed the response, whereas bio-naive patients had faster first-year outcomes. METHODOLOGY: Researchers conducted an observational retrospective study of patients with moderate-to-severe psoriasis, with or without psoriatic arthritis, at the Turin University Hospital between 2020 and 2024. A total of 545 adult participants (mean age at psoriasis onset, 33.3 years; 60.1% men) received risankizumab 150 mg at weeks 0 and 4 and then every 12 weeks subsequently. Study outcomes were the achievement of Psoriasis Area and Severity Index (PASI) 100 and PASI 90 at various timepoints between weeks 16 and 208. Drug survival, defined as the time from initiation to discontinuation, was evaluated alongside predictors of response to risankizumab including obesity, bio-naive status, and difficult-to-treat sites. TAKEAWAY: The mean PASI score decreased significantly from 14 at baseline to 0.4 at week 208. PASI 100 responses increased from 33% at week 16 to 74% at week 208, and PASI 90 responses increased from 47% to 85% over the same period. Bio-naive patients achieved PASI 100 more often than bio-experienced patients at week 16 (38% vs 27%; P = .025), week 28 (63% vs 44%; P < .001), and week 52 (73% vs 57%; P = .002); similar trends were seen for PASI 90. Similarly, patients without obesity were significantly more likely than those with obesity to achieve PASI 100 (66% vs 55%; P = .029) and PASI 90 (78% vs 63%; P = .012) at week 52. Drug survival was notably high at 87.2% for the observed cases after week 208. The presence of a difficult-to-treat site significantly reduced the risk for interruption (hazard ratio, 0.15; P < .001). Overall, 11.6% of patients discontinued the treatment, with the leading cause being secondary failure (38.1%), and adverse events prompted discontinuation in 13 patients. IN PRACTICE: "Risankizumab showed excellent effectiveness, safety, and DS [drug survival] over 4 years of treatment," the authors wrote. "Obesity and involvement of a difficult-to-treat area can lower the initial response, even if they did not affect treatment interruption," they concluded, observing that "bio-naïve patients benefit from a faster response during the first year of treatment." SOURCE: This study was led by Luca Mastorino, Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. It was published online on July 23, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The analysis of observed cases and those lost to follow-up weakened the 4-year survival estimate, showcasing an inherent limitation of real-world studies. Additionally, this study could not differentiate effectiveness on the basis of different difficult-to-treat sites. DISCLOSURES: This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
